Stocks and Investing Stocks and Investing
Mon, June 17, 2024
Fri, June 14, 2024

Matthew Kaplan Maintained (URGN) at Strong Buy with Increased Target to $54 on, Jun 14th, 2024


Published on 2024-10-28 11:57:20 - WOPRAI, Matthew Kaplan
  Print publication without navigation


Matthew Kaplan of Ladenburg Thalmann, Maintained "UroGen Pharma Ltd." (URGN) at Strong Buy with Increased Target from $48 to $54 on, Jun 14th, 2024.

Matthew, nor any peers, have made any analyst calls on URGN in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources